Mesirow Financial Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Mesirow Financial Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,242	Closed	-$115K	–	604
2025 Q1	$115K	Hold	10,242	–	–	﹤0.01%	559
2024 Q4	$135K	Buy	10,242 +116	+1%	+$1.99K	﹤0.01%	566
2024 Q3	$195K	Buy	+10,126	New	+$209K	﹤0.01%	549
2024 Q1	–	Sell	-16,024	Closed	-$358K	–	596
2023 Q4	$358K	Buy	16,024 +3,741	+30%	+$57.5K	0.01%	381
2023 Q3	$178K	Hold	12,283	–	–	0.78%	75
2023 Q2	$257K	Buy	+12,283	New	+$256K	1.09%	49
2021 Q2	–	Sell	-894	Closed	-$20K	–	125
2021 Q1	$20K	Buy	894 +382	+75%	+$8.63K	0.05%	88
2020 Q4	$11.4K	Buy	+512	New	+$10.6K	0.04%	82

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Mesirow Financial Investment Management's SNDX Position: Q2 2025 in Review

Mesirow Financial Investment Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 10,242 shares — an estimated $115K sold.

Mesirow Financial Investment Management first reported a position in SNDX in Q4 2020 and held it in 8 quarters. The position peaked at $358K in Q4 2023. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

Mesirow Financial Investment Management reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Mesirow Financial Investment Management sold 10,242 Syndax Pharmaceuticals shares in Q2 2025, an estimated $115K.
Mesirow Financial Investment Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Mesirow Financial Investment Management's Syndax Pharmaceuticals position peaked at $358K in Q4 2023.
216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2025, filed 4 Aug 2025.